Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Phase II Study of Pemetrexed and Carboplatin in the Treatment of Esophageal Cancer

This study has been terminated.
(Low accrual)
Sponsor:
Collaborator:
Eli Lilly and Company
Information provided by (Responsible Party):
Washington University School of Medicine
ClinicalTrials.gov Identifier:
NCT00383266
First received: October 2, 2006
Last updated: August 9, 2013
Last verified: August 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: June 2010
  Primary Completion Date: November 2009 (Final data collection date for primary outcome measure)